The value of timely treatment with anti‐amyloid therapy for Alzheimer’s disease

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Anti-amyloid therapies can slow Alzheimer’s disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for...

Genetic evidence supports a cortical neuroprotective role of GLP‐1 receptor activation in Alzheimer’s disease: A drug‐target Mendelian randomization study

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Whether glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation lowers Alzheimer’s disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain-cortex cis-acting...

miR‐214‐3p and NCKAP1: A microglial functional dimension of Alzheimer’s progression

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Biological Alzheimer’s disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient-derived induced microglia-like cell (iMG) profiles capture a functional...

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Anti-amyloid antibody clinical trials with a high proportion of participants reaching treatment-related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the...

Cognitive impairment in Parkinson disease correlates with loss of cholinergic axon projections to cortex in an autopsy study

by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia

Abstract INTRODUCTION People with Parkinson’s disease (PD) frequently develop dementia. We investigated the relationship between cognitive impairment and the loss of cholinergic axon projections from the nucleus basalis of Meynert to neocortical regions in PD....

A murine model of amyloid enhanced tauopathy: progressive changes in tau pathology and behavior

by Clinical Neuropsychologist Online | Tuesday, October 6, 2026 | Dementia

Abstract BACKGROUND Our prior work demonstrated systemic P301L-tau injections in mice with mature amyloid resulted in several-fold enhancement of tauopathy compared to non-transgenic (NTg) littermates. METHODS APP+PS1 mice were injected intravenously with AAV.CAP-B10...